Myriad Genetics Inc (MYGN) is a publicly traded Healthcare sector company. As of November 3, 2026, MYGN trades at $5.93 with a market cap of $607.38M and a P/E ratio of -3.80. MYGN moved -8.35% today. Year to date, MYGN is -5.13%; over the trailing twelve months it is -27.55%. Its 52-week range spans $2.74 to $11.44. Analyst consensus is neutral with an average price target of $3.83. Rallies surfaces MYGN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Myriad agrees to sell prenatal testing business to Labcorp for $210 million: Myriad agreed to sell its prenatal testing business to Labcorp for $210 million in cash plus inventory value, with closing expected by early 2027. Separately, its Precise MRD test detected colorectal cancer recurrence a median of four months before clinical surveillance in a study, with findings scheduled for presentation on October 25, 2026.
| Metric | Value |
|---|---|
| Price | $5.93 |
| Market Cap | $607.38M |
| P/E Ratio | -3.80 |
| EPS | $-1.18 |
| Dividend Yield | 0.00% |
| 52-Week High | $11.44 |
| 52-Week Low | $2.74 |
| Volume | 804.37K |
| Avg Volume | 0 |
| Revenue (TTM) | $806.60M |
| Net Income | $-112.60M |
| Gross Margin | 68.83% |
8 analysts cover MYGN: 0 strong buy, 1 buy, 4 hold, 3 sell, 0 strong sell. Consensus rating is neutral. Average price target: $3.83.